Insider Selling: CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Sells $325,000.00 in Stock

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of the company’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $0.10, for a total value of $325,000.00. Following the completion of the sale, the insider now owns 22,620,783 shares in the company, valued at approximately $2,262,078.30. This represents a 12.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

CERo Therapeutics Trading Up 52.4 %

CERO opened at $0.29 on Friday. The firm has a fifty day moving average price of $0.10 and a 200 day moving average price of $0.35. CERo Therapeutics Holdings, Inc. has a 1 year low of $0.06 and a 1 year high of $12.80.

CERo Therapeutics (NASDAQ:CERO) last posted its earnings results on Wednesday, August 14th. The company reported ($0.33) earnings per share (EPS) for the quarter.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.